Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 25;9:746317. doi: 10.3389/fcell.2021.746317

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhang, Lei, Meng, Liu, Li, Zhang, Zhang, Tao, Peng, Lin and Ji.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Schematic diagram of the experimental design and major process in the present study. (A) Flow chart of processing data in GSE160516 dataset. (B) Experiment design 1 was performed to demonstrate the time course of changes in mRNA expression of COX2 and NLRP3 after myocardial reperfusion. (C) Experiment design 2 was conducted to investigate the therapeutic effect of Iguratimod pretreatment on myocardial injury induced by I/R and the underlying mechanism. (D,E) Experiment design 3 was carried out to explore the optimal concentration of iguratimod for mitigating H/R injury of primary cardiac fibroblasts. (F) Experiment design 4 assessed the implications of iguratimod on pyroptosis of cardiac fibroblasts in vitro H/R model. I/R, ischemia/reperfusion; H/R, hypoxia/reoxygenation.